August 2020 Cancer Epidemiology Matters E-News
Cancer Epidemiology Matters E-News
- Data Resources from NIH’s All of Us Research Program
- NCI Funding Opportunities
- Other Relevant NIH Funding Opportunities (NCI not participating)
- Contract Solicitations
- Grants Policy Notices
- NCI/NIH Blog Posts
Data Resources from NIH’s All of Us Research Program
At the end of May, NIH announced that a beta version of the All of Us Researcher Workbench—a cloud-based research platform—was available for researchers to begin using through the Program’s Research Hub. The Workbench contains a suite of custom tools that are available to approved researchers while using the initial All of Us dataset.
The Researcher Workbench data currently includes:
- Survey data for 224,000+ participants (including lifestyle, access to care, medical history, and more)
- Physical measurements for 188,000+ participants (including blood pressure, heart rate, BMI, and more)
- EHR data for 127,000+ participants (including demographics, visits, diagnoses, and medication data, harmonized according to the common data model)
NIH will continue to improve the experience and add additional data and tools over time — including genomics, wearables, COVID-19 data, and more — using input and feedback from beta testers.
Data from the All of Us Research Program is divided into two different tiers: one tier for the general public and a restricted tier for registered researchers.
For the general public, the All of Us Research Program offers a Data Browser that provides interactive views of publicly available participant data, including surveys and physical measures taken at the time of enrollment and electronic health record data reported by health care providers. A data snapshots page provides an overview of the All of Us participant characteristics and the types of data collected from participants. Examples of information included in the data snapshots include enrollment numbers, geographic distribution, self-reported race, ethnicity, age, and gender identity information.
U.S.-based academic, nonprofit, or health care organization researchers with NIH eRA Commons accounts may apply for access to the Researcher Workbench if their institutions have signed a data use agreement with the program. Learn more about the application process.
Approved registered users can use Jupyter Notebooks to review and annotate cohorts; build and view cohorts and datasets; and perform high-powered queries and analyses within the dataset. Researchers will need to code in R or Python to analyze the data. The Workbench platform can help users find partners from other disciplines with whom they can collaborate. See how researchers are currently using data in the registered tier by viewing the Research Projects Directory.
A searchable list of publications that describe the development of participant provided information modules, informatics implementation, best practices for participant and stakeholder engagement, and implementation of a universal informed consent process is available on the All of Us website.
If you are interested in learning more or becoming a beta user, visit researchallofus.org/workbench.
NCI Funding Opportunities
- Automatic Detection and Tracing of SARS-CoV-2 (U01, Clinical Trial Not Allowed)
- Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18, Clinical Trial Not Allowed)
- Core Infrastructure Support for Cancer Epidemiology Cohorts (U01, Clinical Trial Not Allowed)
- Ethical, Legal and Social Implications Research (R01, R21, R03, Clinical Trial Optional)
- Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)
- Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01, R21, Clinical Trial Not Allowed)
- Fertility Status as a Marker for Overall Health (R01, R21, Clinical Trial Optional)
- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult Cancer Survivors (R01, R21, Clinical Trial Optional)
- Research to Improve Native American Health (R21, Clinical Trials Optional)
- Intervention Research to Improve Native American Health (R01, Clinical Trial Optional)
- Gastrointestinal and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33, Clinical Trial Required; NOT-DK-20-001, Notice of Special Interest (NOSI))
- Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolite and Hormones (R21/R33, Clinical Trial Required; NOT-DK-20-002, NOSI)
- Notice of Special Interest: Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)
- Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (NOT-RM-20-023)
- Notice of Intent to Publish a Funding Opportunity Announcement for NIH FIRST Coordination and Evaluation Center (NOT-RM-20-022)
Other Relevant NIH Funding Opportunities (NCI not participating)
- Systematic Characterization of Genomic Variation on Genome Function and Phenotype (UM1, Clinical Trial Not Allowed)
- Defining Genomic Influence on Gene Network Regulation (U01, Clinical Trial Not Allowed)
- Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function (UM1, Clinical Trial Not Allowed)
- Genomic Variation and Function Data and Administrative Coordinating Center (U24, Clinical Trial Not Allowed)
- Developing Predictive Models of the Impact of Genomic Variation on Function (U01, Clinical Trial Not Allowed)
- Notice of Pre-Application Webinars for the Impact of Genomic Variation on Function (IGVF) Consortium FOAs (NOT-HG-20-055)
- NCI Small Business Innovation Research Program (PHS 2021-1). Topics relevant to population scientists include:
- Next Generation 3D Tissue Culture Systems with Tertiary Lymphoid Organs (Topic 413)
- Understanding Cancer Tumor Genomic Results: Technology Applications for Providers (Topic 419)
- Single-Cell “Unbiased Discovery” Proteomic Technologies (Topic 420)
- Software to Address Social Determinants of Health in Oncology Practices (Topic 423)
- Digital Tools to Improve Health Outcomes in Pediatric Cancer Survivors (Topic 424)
- Information Technology Tools for Automated Analysis of Physical Activity, Performance, and Behavior from Images for Improved Cancer Health (Topic 425)
Grants Policy Notices
- Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic (NOT-OD-20-163)
- Policy Update – Results Information Reporting for Applicable Clinical Trials (NOT-OD-20-147)
- Upcoming Changes to the Notice of Award Beginning October 1, 2020 (NOT-OD-20-155)
- Process for Submitting Large Budget Cancer Epidemiology Grant Applications ( ≥ $500,000)
NCI/NIH Blog Posts
- Charting a Rapid Course Toward Better COVID-19 Tests and Treatments
- NCI Initiatives on the Human Response to SARS-CoV-2
- An Early Look at Applications Submitted During the Pandemic
- Study Offers Insights on Health Problems among AYA Cancer Survivors
- Leveraging Standardized Clinical Data to Advance Discovery
- Institute and Center Award Rates and Funding Disparities
- NIH Helps Small Businesses Change the World